StockDriftsStockDriftsIntellia Therapeutics, Inc. has 2 SEC filings in the last 90 days, latest: FDA accepts BLA for Lonvo-z with Priority Review for HAE (8-K, September 8, 2026). Each filing below is summarised from the document itself and links straight to the original on SEC EDGAR.
Intellia Therapeutics obtained a $400 million senior secured credit facility with an initial $75 million funded at closing.
FDA accepted the Biologics License Application for lonvoguran ziclumeran (Lonvo-z) and granted Priority Review with a PDUFA target action date of March 10, 2027.